Blog

AUTHORS Atsuko Sangria, PhD, Director, Drug Substance Process Development, Kudo Biotechnology Aaron Chung, Director, Nucleic Acid Platforms, LineaRx/Applied DNA SciencesYuhua Sun, Executive Director of R&D, LineaRx/Applied DNA Sciences Overview mRNA therapeutics offer benefits far beyond pandemic vaccines, including cancer vaccines, protein replacement, and cell and gene therapies. Swift development and delivery are crucial, as delays […]

Realizing the full clinical potential of circular and self-amplifying RNAs across infectious diseases, CAR-T therapy, gene therapy and beyond with improved efficacy, functionality and immunogenicity. May 28 – 29, 2025 • Boston, MA

Signals Start of New Commercialization Phase for LineaRx SubsidiaryCompany Negotiating GMP Supply AgreementCompany Reaffirms Strategic Restructuring Timeline STONY BROOK, N.Y., January 10, 2025 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the “facility”) […]

Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies STONY BROOK, N.Y., December 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic […]

Fast track your mRNA-based vaccines and therapeutics from discovery to commercialization by ensuring targeted delivery, durability and tolerable immunogenicity across all disease indicators. July 21-23, 2025 • Boston, MA

LineaRx, an Applied DNA company, will showcase its Linea™ IVT and Linea™ DNA platforms at the 2025 mRNA Process Development & CMC Summit, September 23 – 25 in Boston, MA.

Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing STONY BROOK, N.Y. September 17, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week: LineaRx will present its Linea™ IVT […]

– Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA –    STONY BROOK, N.Y., September 17, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity […]

Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination STONY BROOK, N.Y. – July 29, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 – 31, 2024, in Boston. The poster […]